{"corpus_id":25936189,"paper_sha":"d37cf03d6bbde930051e93903af72a9e5d7edf91","doi":"10.1016/j.leukres.2015.03.015","arxiv_id":null,"pmid":25891070,"pmcid":null,"mag_id":2074320552,"dblp_id":null,"acl_id":null,"title":"Neurotoxicity of stem cell mobilization chemotherapy with vinorelbine in myeloma patients after bortezomib treatment.","year":2015,"publication_date":"2015-07-01","venue":"Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis","journal":{"name":"Leukemia research","pages":"\n          786-92\n        ","volume":"39 7"},"journal_issn":null,"journal_title":null,"publication_types":["JournalArticle"],"pubmed_pub_types":["Journal Article","Research Support, Non-U.S. Gov't"],"s2_fields_of_study":["Medicine"],"reference_count":51,"citation_count":17,"influential_citation_count":0,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Adult","mj":false,"ui":"D000328"},{"d":"Aged","mj":false,"ui":"D000368"},{"d":"Antineoplastic Agents","mj":false,"qs":[{"q":"therapeutic use","mj":true,"ui":"Q000627"}],"ui":"D000970"},{"d":"Boronic Acids","mj":false,"qs":[{"q":"therapeutic use","mj":true,"ui":"Q000627"}],"ui":"D001897"},{"d":"Bortezomib","mj":false,"ui":"D000069286"},{"d":"Female","mj":false,"ui":"D005260"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Male","mj":false,"ui":"D008297"},{"d":"Middle Aged","mj":false,"ui":"D008875"},{"d":"Multiple Myeloma","mj":false,"qs":[{"q":"drug therapy","mj":true,"ui":"Q000188"}],"ui":"D009101"},{"d":"Nervous System","mj":false,"qs":[{"q":"drug effects","mj":false,"ui":"Q000187"}],"ui":"D009420"},{"d":"Pyrazines","mj":false,"qs":[{"q":"therapeutic use","mj":true,"ui":"Q000627"}],"ui":"D011719"},{"d":"Vinblastine","mj":false,"qs":[{"q":"analogs & derivatives","mj":true,"ui":"Q000031"},{"q":"therapeutic use","mj":false,"ui":"Q000627"}],"ui":"D014747"},{"d":"Vinorelbine","mj":false,"ui":"D000077235"}],"chemicals":[{"n":"Antineoplastic Agents","ui":"D000970","reg":"0"},{"n":"Boronic Acids","ui":"D001897","reg":"0"},{"n":"Pyrazines","ui":"D011719","reg":"0"},{"n":"Vinblastine","ui":"D014747","reg":"5V9KLZ54CY"},{"n":"Bortezomib","ui":"D000069286","reg":"69G8BD63PP"},{"n":"Vinorelbine","ui":"D000077235","reg":"Q6C979R91Y"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"https://boris.unibe.ch/77201/8/1-s2%200-S0145212615000867-main.pdf","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/d37cf03d6bbde930051e93903af72a9e5d7edf91","s2_open_access_license":null,"s2_open_access_status":"GREEN","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"Vinorelbine chemotherapy with G-CSF stimulation is the standard mobilization regimen in Switzerland for multiple myeloma patients. However, with the increasing use of bortezomib during induction treatment, adding the neurotoxic compound vinorelbine for mobilization may aggravate bortezomib-induced polyneuropathy. In this retrospective single-center study, we aimed to explore vinorelbine mediated neuropathy in 106 consecutive bortezomib pretreated myeloma patients. We confirmed that vinorelbine with G-CSF represents a reliable and effective regimen for mobilization of autologous stem cells. However, the single administration of 35 mg/m(2) vinorelbine added significant neurotoxicity. We found that 24 patients (24%) reported vinorelbine mediated neurotoxicity: Aggravation of bortezomib-induced neuropathy was observed in 17 patients (17%), and vinorelbine mobilization induced first occurrence of polyneuropathy in additional 7 patients (7%). We observed that development of polyneuropathy was not associated with differing survival rates. Finally, affected patients reported polyneuropathy associated disease burden as \"very high\" in 13% and \"high\" in 50%. Our data indicate that a single administration of vinorelbine to mobilize autologous stem cells is associated with significant additional polyneuropathy in bortezomib pretreated myeloma patients. The efficacy of vinorelbine mobilization should be balanced against its neurotoxic potential.","claims":[{"public_id":"cl_a3222a42dcd949885133a78e85da065f","status":"active","text":"A single administration of 35 mg/m² vinorelbine adds significant neurotoxicity in this setting.","confidence":0.97,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_a3222a42dcd949885133a78e85da065f"},{"public_id":"cl_b333e690a6284aa6259d627224f58d31","status":"active","text":"Affected patients reported polyneuropathy-associated disease burden as very high in 13% and high in 50%.","confidence":0.9,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_b333e690a6284aa6259d627224f58d31"},{"public_id":"cl_4ba1de06ee6020bf54458a53382d6066","status":"active","text":"Development of polyneuropathy was not associated with differing survival rates.","confidence":0.91,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_4ba1de06ee6020bf54458a53382d6066"},{"public_id":"cl_dae71a4c8ad00d3131df023b118d79b0","status":"active","text":"Vinorelbine with G-CSF is a reliable and effective regimen for mobilization of autologous stem cells in bortezomib-pretreated myeloma patients.","confidence":0.96,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_dae71a4c8ad00d3131df023b118d79b0"},{"public_id":"cl_6827ab459c2e2f2c0501183a4c133161","status":"active","text":"Vinorelbine-mediated neurotoxicity was reported in 24% of patients, including aggravation of bortezomib-induced neuropathy in 17% and first occurrence of polyneuropathy in 7%.","confidence":0.98,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_6827ab459c2e2f2c0501183a4c133161"}],"concepts":[{"public_id":"co_00bb7c9cee749533a243e42778784556","status":"active","name":"bortezomib-induced neuropathy","description":"Peripheral neuropathy attributed to prior bortezomib treatment.","types":["adverse effect"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_00bb7c9cee749533a243e42778784556"},{"public_id":"co_07b8ad2341b264c82ca46211d61689cd","status":"active","name":"polyneuropathy-associated disease burden","description":"Patients' reported burden and severity impact associated with polyneuropathy.","types":["patient-reported outcome"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_07b8ad2341b264c82ca46211d61689cd"},{"public_id":"co_07ed74b7786c07a816db888e8a5ae0ca","status":"active","name":"mobilization of autologous stem cells","description":"The process of collecting a patient's own stem cells for transplantation.","types":["procedure"],"aliases":["autologous stem cell mobilization"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_07ed74b7786c07a816db888e8a5ae0ca"},{"public_id":"co_127a29ec23876041bc1425a9ee9e3774","status":"active","name":"vinorelbine","description":"A chemotherapeutic agent used here as part of stem cell mobilization.","types":["drug"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_127a29ec23876041bc1425a9ee9e3774"},{"public_id":"co_169aa132615f8f91c96509aa2fb1b0fb","status":"active","name":"vinorelbine with G-CSF","description":"A stem cell mobilization regimen combining vinorelbine chemotherapy with granulocyte colony-stimulating factor.","types":["treatment regimen"],"aliases":["vinorelbine chemotherapy with G-CSF stimulation"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_169aa132615f8f91c96509aa2fb1b0fb"},{"public_id":"co_66b48a172ee2e51809dc369ad7d28791","status":"active","name":"survival rates","description":"The proportion of patients surviving over a specified period.","types":["outcome measure"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_66b48a172ee2e51809dc369ad7d28791"},{"public_id":"co_9b0e1fbc8e6df2c85d5f5dc394ac8539","status":"active","name":"neurotoxicity","description":"Adverse toxic effects on the nervous system associated here with vinorelbine exposure.","types":["adverse effect"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_9b0e1fbc8e6df2c85d5f5dc394ac8539"},{"public_id":"co_9ccf91e6bfaaa086856c8e50a9d3aa9c","status":"active","name":"bortezomib-pretreated myeloma patients","description":"Multiple myeloma patients who had previously received bortezomib during induction treatment.","types":["patient group"],"aliases":["myeloma patients after bortezomib treatment"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_9ccf91e6bfaaa086856c8e50a9d3aa9c"},{"public_id":"co_9e3e879fd71bc8ae5bb9bbd70a856fb3","status":"active","name":"35 mg/m² vinorelbine","description":"A single-dose vinorelbine administration of 35 milligrams per square meter.","types":["dose"],"aliases":["single administration of 35 mg/m(2) vinorelbine"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_9e3e879fd71bc8ae5bb9bbd70a856fb3"},{"public_id":"co_a9edc6d4d09c3d668bfdca9329d078c5","status":"active","name":"vinorelbine-mediated neurotoxicity","description":"Neurologic toxicity reported after vinorelbine administration.","types":["adverse effect"],"aliases":["vinorelbine mediated neuropathy"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_a9edc6d4d09c3d668bfdca9329d078c5"},{"public_id":"co_c5d96ffce91c79cb72705a929b9c6241","status":"active","name":"affected patients","description":"Patients who experienced vinorelbine-related neuropathy or polyneuropathy in the study.","types":["patient group"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_c5d96ffce91c79cb72705a929b9c6241"},{"public_id":"co_d2e7f77c3c9ea7fb48c3232c18b2aaa5","status":"active","name":"polyneuropathy","description":"A disorder involving dysfunction of multiple peripheral nerves.","types":["condition"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_d2e7f77c3c9ea7fb48c3232c18b2aaa5"}],"external_ids":{"DOI":"10.1016/j.leukres.2015.03.015","ArXiv":null,"PubMed":25891070,"PubMedCentral":null,"MAG":2074320552,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"https://boris.unibe.ch/77201/8/1-s2%200-S0145212615000867-main.pdf","landing_url":"https://www.semanticscholar.org/paper/d37cf03d6bbde930051e93903af72a9e5d7edf91","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":null,"status":"GREEN","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":638227,"paper_uid":"54434ff1-8939-4ef0-a479-568e3007be4d","canonical_identity":{"paper_id":638227,"paper_uid":"54434ff1-8939-4ef0-a479-568e3007be4d","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/25936189"}